跳转至内容
Merck
CN

SML2719

Sigma-Aldrich

AVE 0991

≥98% (HPLC)

别名:

1-Ethyl-3-[3-[4-[(5-formyl-4-methoxy-2-phenylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea, 5-Formyl-4-methoxy-2-phenyl-1[[4-[2-(ethylaminocarbonylsulfonamido)-5-isobutyl-3-thienyl]-phenyl]-methyl]-imidazole, AVE-0991, AVE0991, N-[(Ethylamino)carbonyl]-3-[4-[(5-formyl-4-methoxy-2-phenyl-1H-imidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)-2-thiophenesulfonamide

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C29H32N4O5S2
化学文摘社编号:
304462-19-9
分子量:
580.72
MDL编号:
MFCD27992063
UNSPSC代码:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

O=CC(N1CC2=CC=C(C=C2)C3=C(SC(CC(C)C)=C3)S(NC(NCC)=O)(=O)=O)=C(N=C1C4=CC=CC=C4)OC

InChI

1S/C29H32N4O5S2/c1-5-30-29(35)32-40(36,37)28-24(16-23(39-28)15-19(2)3)21-13-11-20(12-14-21)17-33-25(18-34)27(38-4)31-26(33)22-9-7-6-8-10-22/h6-14,16,18-19H,5,15,17H2,1-4H3,(H2,30,32,35)

InChI key

QTOZBSNPDCWHPV-UHFFFAOYSA-N

相关类别

生化/生理作用

AVE 0991 is an orally active, non-peptide-based selective Ang (1-7) receptor (Mas, MasR) agonist with 5-times NO-inducing efficacy than Ang (1-7) in bovine aortic endothelial cell (BAEC) cultures (10 μM; BAEC) and 10-fold higher affinity (IC50 = 21 nM vs 220 nM, respectively, against 10 nM [125I]-Ang-(1-7) for BAEC membrane binding), exhibiting little affinity toward AT1 & AT2 receptors. AVE 0991 is a widely probing Mas-mediated responses in cultures (0.01-10 μM) and in animal disease models in vivo (0.3-10 mg/kg via ip., po. or intranasal; rats and mice).
Orally active, non-peptide-based selective Ang (1-7) receptor (Mas, MasR) agonist in vitro and in vivo.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000130300
0000130301
0000126733

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Valeria Burghi et al.
Frontiers in pharmacology, 10, 146-146 (2019-03-12)
The MasR receptor (MasR) is an orphan G protein-coupled receptor proposed as a candidate for mediating the angiotensin (Ang)-converting enzyme 2-Ang-(1-7) protective axis of renin-angiotensin system. This receptor has been suggested to participate in several physiological processes including cardio- and
Lirong Guo et al.
American journal of physiology. Heart and circulatory physiology, 312(5), H980-H991 (2017-04-16)
The objectives of the present study were to investigate the effect of ANG-(1-7) on the development of cardiac hypertrophy and to identify the intracellular mechanism underlying this action of ANG-(1-7). Blood pressure and heart rate were recorded using radiotelemetry before
Gabriele Wiemer et al.
Hypertension (Dallas, Tex. : 1979), 40(6), 847-852 (2002-12-07)
Recently, we demonstrated that the heptapeptide angiotensin-(1-7) (Ang-[1-7]) exhibits a favorable kinetic of nitric oxide (NO) release accompanied by extremely low superoxide (O2-) production. In this report we describe AVE 0991, a novel nonpeptide compound that evoked effects similar to
Kate T Murphy et al.
Cancer research, 79(4), 706-719 (2018-11-14)
Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal muscle mass associated with significant functional impairment. Cachexia robs patients of their strength and capacity to perform daily tasks and live independently. Effective treatments are needed urgently.
Gurkirat S Brar et al.
Diabetes, 66(8), 2201-2212 (2017-06-01)
Recent work has renewed interest in therapies targeting the renin-angiotensin system (RAS) to improve β-cell function in type 2 diabetes. Studies show that generation of angiotensin-(1-7) by ACE2 and its binding to the Mas receptor (MasR) improves glucose homeostasis, partly
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持